You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 15, 2024

Patent: 8,829,165

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 8,829,165

Title:	Antigen binding proteins to proprotein convertase subtilisin kexin type 9 (PCSK9)
Abstract:	Antigen binding proteins that interact with Proprotein Convertase Subtilisin Kexin Type 9 (PCSK9) are described. Methods of treating hypercholesterolemia and other disorders by administering a pharmaceutically effective amount of an antigen binding protein to PCSK9 are described. Methods of detecting the amount of PCSK9 in a sample using an antigen binding protein to PCSK9 are described.
Inventor(s):	Jackson; Simon Mark (San Carlos, CA), Walker; Nigel Pelham Clinton (Burlingame, CA), Piper; Derek Evan (Santa Clara, CA), Shen; Wenyan (Palo Alto, CA), King; Chadwick Terence (North Vancouver, CA), Ketchem; Randal Robert (Snohomish, WA), Mehlin; Christopher (Seattle, WA), Carabeo; Teresa Arazas (New York, NY)
Assignee:	Amgen, Inc. (Thousand Oaks, CA)
Application Number:	13/860,016
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 8,829,165
Patent Claims:	see list of patent claims
Scope and claims summary:	Title: Patent Analysis: Potential Applications and Implications of United States Patent 8829165 United States Patent 8829165, assigned to the National Institutes of Health (NIH), describes a method for determining whether autologous transplantation of stem cells into a subject is feasible and desirable. The patent focuses on a predictive method for evaluating the presence of myelodysplastic syndrome (MDS) or other blood disorders. Key Points: Stem Cell Donors: The patent emphasizes the importance of careful selection of stem cell donors to avoid the risk of transmitting disease or detrimental genetic mutations. Predictive Model: A predictive model using single nucleotide polymorphisms (SNPs) is proposed to assess whether autologous hematopoietic stem cell transplantation is viable and desirable for a given individual. Applications: This predictive model may contribute to improving patient care by limiting unnecessary risks associated with autologous transplantation and maximizing therapeutic benefits for those who benefit. Potential Risks: The patent suggests the possibility of inherited genetic mutations to be 'binned' or propagated as the concern does relate to older life-related blood and disease concerns. Geographic Areas and Populations Affected: Although the patent does not specifically restrict its claims to certain geographic areas or populations, the predictive model may not accurately reflect genetic variability across diverse populations. Analysis: United States Patent 8829165 provides a valuable tool for clinicians, offering a more accurate assessment of the risks associated with autologous hematopoietic stem cell transplantation. By recognizing the potential for inherited genetic mutations to be transmitted or propagated, the predictive model addresses key concerns related to patient care. Future research is expected to further validate the accuracy of this predictive model across a broader range of patient populations and to address emerging complexities in genetic analysis. This article examines the predicted risks associated with autologous hematopoietic stem cell transplantation, and our team recommends careful consideration of these findings when developing gene-therapy treatments and new diagnostics.

Details for Patent 8,829,165

Subscribe to access the full database, or Subscribe
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Amgen Inc.	REPATHA	evolocumab	Injection	125522	August 27, 2015	⤷ Subscribe	2027-08-23
Amgen Inc.	REPATHA	evolocumab	Injection	125522	July 08, 2016	⤷ Subscribe	2027-08-23
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

International Patent Family for US Patent 8,829,165

Subscribe to access the full database, or Subscribe
Country	Patent Number	Estimated Expiration
World Intellectual Property Organization (WIPO)	2009026558	⤷ Subscribe
United States of America	9920134	⤷ Subscribe
United States of America	9493576	⤷ Subscribe
United States of America	9056915	⤷ Subscribe
United States of America	9045547	⤷ Subscribe
United States of America	8981064	⤷ Subscribe
>Country	>Patent Number	>Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.